These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30442630)

  • 1. A case of juvenile localized scleroderma with anti-topoisomerase I antibody.
    Shimizu K; Matsushita T; Takehara K; Hamaguchi Y
    Eur J Dermatol; 2019 Aug; 29(4):443-444. PubMed ID: 30442630
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-topoisomerase I/Scl-70 antibody].
    Kuwana M
    Nihon Rinsho; 2010 Jun; 68 Suppl 6():545-7. PubMed ID: 20942125
    [No Abstract]   [Full Text] [Related]  

  • 3. [Progress in clinical tests and the pathophysiological study of collagen diseases--anti-topoisomerase I antibodies and anticentromere antibodies].
    Konndo H
    Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2409-13. PubMed ID: 9922659
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
    Hayakawa I; Hasegawa M; Takehara K; Sato S
    Arthritis Rheum; 2004 Jan; 50(1):227-32. PubMed ID: 14730620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma.
    Stojanov L; Satoh M; Dooley MA; Kuwana M; Jennette JC; Reeves WH
    Lupus; 1995 Aug; 4(4):314-7. PubMed ID: 8528230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihistone antibodies in patients with localized scleroderma.
    Sato S; Ihn H; Soma Y; Igarashi A; Tamaki T; Kikuchi K; Ishibashi Y; Takehara K
    Arthritis Rheum; 1993 Aug; 36(8):1137-41. PubMed ID: 8343189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
    Benyamine A; Bertin D; Heim X; Granel B; Bardin N
    Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-agalactosyl immunoglobulin G antibodies in localized scleroderma.
    Mimra Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
    Int J Dermatol; 2005 Oct; 44(10):817-20. PubMed ID: 16207181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies.
    Fredi M; Cavazzana I; Zanola A; Carabellese N; Tincani A; Mahler M; Franceschini F
    Lupus; 2017 Sep; 26(10):1121-1122. PubMed ID: 28420064
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
    Katsumi S; Kobayashi N; Yamamoto Y; Miyagawa S; Shirai T
    Br J Dermatol; 2000 May; 142(5):1030-3. PubMed ID: 10809868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of Antitopoisomerase I Antibody Alone May Not Be Sufficient for the Diagnosis of Systemic Sclerosis.
    Tebo AE; Schmidt RL; Frech TM
    J Rheumatol; 2019 Apr; 46(4):440-442. PubMed ID: 30824655
    [No Abstract]   [Full Text] [Related]  

  • 12. Late onset systemic sclerosis with seronegativity: a rare presentation of an uncommon disease.
    Saxena D; Jain D; Yadav M; Giri K; Yadav T; Jain P
    Reumatismo; 2019 Oct; 71(3):166-170. PubMed ID: 31649382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Juvenile systemic sclerosis: report of three cases and review of Japanese published work.
    Aoyama K; Nagai Y; Endo Y; Ishikawa O
    J Dermatol; 2007 Sep; 34(9):658-61. PubMed ID: 17727371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical characteristics of patients with juvenile localized scleroderma].
    Sun QN; Du W; Hu B; Liu P; Yuan X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):48-50. PubMed ID: 19317059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiology rounds. Scleroderma.
    Margolis M; McLennan MK
    Can Fam Physician; 1994 Apr; 40():667, 671-4. PubMed ID: 8199518
    [No Abstract]   [Full Text] [Related]  

  • 16. Antinuclear autoantibody profile in systemic sclerosis patients who are negative for anticentromere and anti-topoisomerase I specificities.
    Caramaschi P; Tonolli E; Biasi D; Caimmi C; Pieropan S; Dal Forno I; Scambi C; Adami S
    Joint Bone Spine; 2015 May; 82(3):209-10. PubMed ID: 25543274
    [No Abstract]   [Full Text] [Related]  

  • 17. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?
    Diot E; Giraudeau B; Diot P; Degenne D; Ritz L; Guilmot JL; Lemarié E
    Chest; 1999 Sep; 116(3):715-20. PubMed ID: 10492277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Scleroderma associated autoantibodies - clinical and diagnostic relevance].
    Mierau R; Genth E
    Z Rheumatol; 2006 Jul; 65(4):279-84. PubMed ID: 16788839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I.
    Andrade LEC; Klotz W; Herold M; Conrad K; Rönnelid J; Fritzler MJ; von Mühlen CA; Satoh M; Damoiseaux J; de Melo Cruvinel W; Chan EKL;
    Clin Chem Lab Med; 2018 Sep; 56(10):1783-1788. PubMed ID: 29813025
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
    Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
    Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.